The Centers for Diabetes Care at NewYork-Presbyterian take an active role in using innovative treatments and educating the public on how to prevent this chronic disease. They also address a wide range of metabolic and endocrine disorders, including primary hyperparathyroidism, osteoporosis, transplantation-related bone disease, and Paget's Disease. The Naomi Berrie Diabetes Center at NewYork-Presbyterian/Columbia University Irving Medical Center is one of three Diabetes Centers of Excellence in New York State and has been cited by the American Diabetes Association for its quality care.
Enhancing the Functionality of Pancreatic Beta Cells in Type 2 Diabetes
Weill Cornell Medicine endocrinologists discover a novel mechanism to stimulate growth of pancreatic beta cells in a preclinical model of type 2 diabetes.
Assessing Long-Term Outcomes of Anti-Obesity Medications
Weill Cornell Medicine’s Comprehensive Weight Control Center is at the forefront of research for anti-obesity medications that potentially help individuals lose between 5% to 10% of their body weight.
The Complex Relationship Between Celiac Disease and Metabolic Bone Disease
The Double Bind of Obesity and Chronic Kidney Disease: Evaluating the Impact of the Revised eGFR Formula
A Weill Cornell Medicine transplant surgeon and obesity specialist evaluates the potential impact of the recent changes to the eGFR on obesity medications for Black patients with chronic kidney disease.
Insulin Resistance: A Pathway to Research in Fatty Liver Disease?
A Columbia endocrinologist merges his clinical practice and research pursuits to understand the role of insulin resistance in the development of fatty liver disease.
Insulin Pumps and Continuous Glucose Monitors: Understanding Their Use in the Hospital Setting
Weill Cornell Medicine endocrinologists present current guidelines and available evidence on the continuation of insulin pumps and CGMs by patients when admitted to the hospital.
Thyroid Nodules: Series of Clinical Trials Show the Promise of Radiofrequency Ablation
Columbia endocrine surgeon-scientist evaluates minimally invasive treatment for benign thyroid nodules.
New Medication Surmounts the Challenges of Weight Control
Weill Cornell Medicine obesity medicine specialist served as co-investigator in the SURMOUNT-1 phase 3 trial of tirzepatide, which achieved unprecedented levels of weight loss in adults with obesity.
Confronting the Challenges of Osteoporosis Management in Younger Adults
Columbia endocrinologist defines dilemmas in diagnosis and management of early-onset osteoporosis, exposing the barriers to care and proposing a framework for effective treatment.
A Role for Telemedicine in Weight Loss Management
Weill Cornell Medicine endocrinologists and weight control specialists compare effectiveness of the telemedicine model versus in-person care.
The Multiple Implications of Vitamin D Deficiency
Columbia endocrinologists investigate its role in disease and health and explore its significance for COVID-19.
Interventional Endocrinology: An Emerging Specialty
Doctors at NewYork-Presbyterian/Columbia are looking to interventional endocrinology, an emerging specialty that uses percutaneous, image-guided, less-invasive procedures to address endocrine disorders that offers an alternative to surgery.
Exploring Novel Treatments for Thyroid Cancer
Under the direction of Dr. Thomas J. Fahey, III, researchers at Weill Cornell Medicine have identified the use of gene expression analysis to discriminate benign and malignant thyroid nodules.
Meeting the Pressing Need for Evidence-Based Obesity Care
Research is a key component of the Weight Control Center. Dr. Korner is the principal investigator of an NIH-funded study to understand the hormonal regulation of appetite and energy balance.
Managing the Challenges of Pregnancy and Diabetes
Physicians at Weill Cornell Medicine reviewed the diagnostic criteria for diabetes in pregnancy; types of therapies available to prevent hyperglycemia; and strategies for reaching inpatient glycemic targets during the peripartum period.
Regulating Metabolism in the Setting of Cancer
Dr. Goncalves has developed a mouse model that recapitulates the cachexia syndrome as they seek interventions – either dietary or metabolic – to help prevent muscle wasting and fat loss.
Pathways to Diabetes Prevention: It’s All Relative
We found that insulin production decreases long before a patient is actually diagnosed with type 1 diabetes. Now that we know that a reduction in insulin production begins earlier on, we can diagnose T1D earlier in patients with antibody screening. So the question became how do we reach these individuals.
Newsletters for Medical Professionals
2022 Issue 1
2021 Issue 2
- Active Surveillance: A Rational Option in Monitoring Low-Risk Thyroid Cancer
- COVID-19 and Diabetes: Importance of Glycemic Management
2021 Issue 1
- Uncovering the Relationship Between COVID-19 and Obesity
- Answering the Call: Fellows Redeployed to Aid During Pandemic
- Exploring Novel Treatments for Thyroid Cancer
- Interventional Endocrinology: An Emerging Specialty
- Dr. Laura Alonso New Chief of Endocrinology at Weill Cornell
- Enhancing Endocrinology Education for Physicians and Patients
- Managing the Challenges of Pregnancy and Diabetes
- Meeting the Pressing Need for Evidence-Based Obesity Care
- Noted Endocrinologist Appointed Chair of Department of Medicine at Weill Cornell
- Obesity: Advancing Treatment Through Clinical Trials
- On the Front Lines of Diabetes Prevention and Treatment
- Type 1 Diabetes: It’s Professional and Very Personal